Glioma remains one of the deadliest brain cancers, characterized by aggressive growth and limited treatment options. In a new study, researchers from Ningxia Medical University uncovered that choline ...
April 2, 2026Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa ...
Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...
What Is Thymidine Kinase 2 Deficiency (TK2d)? Thymidine kinase 2 deficiency (TK2d) mainly causes muscle weakness. It’s a very rare mitochondrial disease. Mitochondria are tiny organ-like structures ...
Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter ...
The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase ...
The Food and Drug Administration (FDA) has granted Fast Track designation to TRI-611 for the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results